Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT03736967. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD). Secondary Objectives are to: * Evaluate the efficacy of REGN3500 in combination with dupilumab compared with placebo treatment in adult patients with moderate-to-severe AD * Assess the safety, tolerability, and immunogenicity of subcutaneous (SC) doses of REGN3500 monotherapy and REGN3500 in combination with dupilumab in adult patients with moderate-to-severe AD * Evaluate the Pharmacokinetic (PK) of REGN3500 monotherapy and REGN3500 in combination with dupilumab in adult patients with moderate-to-severe AD
Study identification
- NCT ID
- NCT03736967
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 206 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 12, 2018 (Actual)
- Primary completion
- Mar 13, 2020 (Actual)
- Completion
- Jul 28, 2020 (Actual)
- Last update posted
- Nov 1, 2021
2018 – 2020
United States locations
- U.S. sites
- 22
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Research Site | Phoenix | Arizona | 85259 | — |
| Regeneron Research Site | Fountain Valley | California | 92708 | — |
| Regeneron Research Site | Long Beach | California | 90808 | — |
| Regeneron Research Site | Los Angeles | California | 90025 | — |
| Regeneron Research Site | Los Angeles | California | 90033 | — |
| Regeneron Research Site | Sacramento | California | 95815 | — |
| Regeneron Research Site | Davie | Florida | 33328 | — |
| Regeneron Research Site | Sandy Springs | Georgia | 30328 | — |
| Regeneron Research Site | Rockville | Maryland | 20850 | — |
| Regeneron Research Site | Bay City | Michigan | 48706 | — |
| Regeneron Research Site | Saint Joseph | Michigan | 49085 | — |
| Regeneron Research Site | Troy | Michigan | 48084 | — |
| Regeneron Research Site | Forest Hills | New York | 11375 | — |
| Regeneron Research Site | New York | New York | 10022 | — |
| Regeneron Research Site | New York | New York | 10029 | — |
| Regeneron Research Site | The Bronx | New York | 10467 | — |
| Regeneron Research Site | High Point | North Carolina | 27262 | — |
| Regeneron Research Site | Norman | Oklahoma | 73071 | — |
| Regeneron Research Site | Portland | Oregon | 97239 | — |
| Regeneron Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Regeneron Research Site | Arlington | Texas | 76014 | — |
| Regeneron Research Site | Richmond | Virginia | 23220 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03736967, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2021 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03736967 live on ClinicalTrials.gov.